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Background: CD8 T-cells play a central role in type 1 diabetes (T1D) by recognizing insulin peptides displayed by MHC.
Results: A novel flexible MHC binding mode accommodates extra C-terminal peptide residues.
Conclusion: Unusual peptide-MHC binding might explain weak TCR affinity of a natural T1D epitope.
Significance:MHC peptide binding can be highly flexible around the F-binding pocket.
The non-obese diabetic mouse model of type 1 diabetes con-
tinues to be an important tool for delineating the role of T-cell-
mediated destruction of pancreatic -cells. However, little is
known about themolecularmechanisms that enable this disease
pathway. We show that insulin reactivity by a CD8 T-cell
clone, known to induce type 1 diabetes, is characterized byweak
T-cell antigen receptor binding to a relatively unstable peptide-
MHC.The structure of thenative 9- and10-mer insulin epitopes
demonstrated that peptide residues 7 and 8 form a prominent
solvent-exposed bulge that could potentially be the main focus
of T-cell receptor binding. The C terminus of the peptide gov-
erned peptide-MHC stability. Unexpectedly, we further demon-
strate a novelmode of flexible peptide presentation inwhich the
MHC peptide-binding groove is able to “open the back door” to
accommodate extra C-terminal peptide residues.
Type 1 diabetes (T1D)7 is an autoimmune disease affecting
children and young adults where CD8 T-cells have recently
been shown to play a central role in pancreatic -cell destruc-
tion (1–7). A number of CD8 T-cell T1D epitopes from the
key autoantigenic target proinsulin have been identified (6, 8,
9). How these autoreactive CD8 T-cells escape thymic selec-
tion and cause pathology in the periphery is still under debate.
However, some evidence suggests that the nature of the inter-
action between the clonally expressed T-cell receptor (TCR)
and self-peptide-major histocompatibility complex class I
(pMHCI) may drive this selection. The strength and/or dura-
tion of binding between the TCR and pMHCI (10), as well as
differentmechanical forces (11), can determine the threshold of
T-cell activation. Accumulated data suggest that most self-re-
active T-cells express TCRs that interact weakly with pMHC
compared with pathogenic T-cells (5, 10, 12, 13). These obser-
vations are compounded by the low stability, predicted or
demonstrated, for many autoimmune-pMHC interactions (5,
14–18). Other molecular investigations of T-cell-induced
autoimmunity have also demonstrated suboptimal TCR bind-
ing through atypical TCR conformation, compared with most
pathogen-specific TCRs (17, 19–21). These factors have previ-
ously been considered to be the basis for poor negative selection
of autoreactive T-cells, whichmay escape from the thymus and
become activated in the periphery, potentially through molec-
ular mimicry (22, 23), and thence induce autoimmunity.
The non-obese diabetic (NOD) mouse model, which devel-
ops spontaneous diabetes, has been widely used for investigat-
ing T1D (24–27). There are many parallels between T1D in
humans and NODmice, and findings in these mice have paved
the way for important discoveries in humans (27, 28). In NOD
mice, in which both genetic susceptibility and environment
play a role in disease development, both CD4 and CD8
T-cells, recognizing a number of different autoantigens (re-
viewed in Ref. 29) are important in autoimmune attack on pan-
creatic islet -cells. We have previously cloned a diabetogenic
CD8 T-cell (G9C8) from the islets of young prediabetic NOD
mice, which lyses islets in vitro and causes diabetes within 5–10
days after transfer to young non-diabetic NODmice and NOD.
scid mice (24, 30). The G9C8 T-cell clone recognizes insulin B
chain amino acids 15–23, and T-cells reacting to this epitope
can be highly represented in the small number of cells in the
early infiltrate (8), although other specificities become more
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dominant later. It has been shown that epitopeswithin the insu-
lin B chain have a prime role in the development of T1D,
because substitution at position 16 of the B chain abolishes
CD4 (31) andCD8T-cell reactivity (8, 32). This region of the
insulin B chain has also been identified as an important autoan-
tigen in humans (26, 33, 34), offering an important model sys-
tem for investigating the human form of the disease.
Here, we used cellular and biophysical methods to investi-
gate the molecular interaction between the G9C8 TCR and the
native insulin B chain 10-mer peptide, 15LYLVCGERGF24
(G9GF) and 9-mer peptide, 15LYLVCGERG23 (G9G) as well as
a heteroclitic form of the peptide, LYLVCGERV (G9V), pre-
sented by H-2Kd. G9V was designed to improve MHC stability
andhas been shown to activateG9C8-likeT-cellsmore strongly
than the native G9G peptide (32), although the molecular basis
for this increased potency has not been fully resolved. We
solved the atomic structures of each of the peptides in complex
with H-2Kd, demonstrating the peptide residues that interact
with the MHC binding groove and identifying the solvent-ex-
posed residues that are most likely to contact the TCR. These
data provide the first molecular insight into CD8 T-cell-in-
duced -cell destruction via recognition of the insulin B chain
in this important disease model of T1D and demonstrate a
novel flexible peptide-MHC binding mode that has broad
implications for T-cell antigen presentation.
Experimental Procedures
CD8 T-cells—Insulin-reactive CD8 T-cells (G9C8) were
isolated from spleen cells from 5–8-week-old transgenic
G9C/ NODmice (30).
[3H]Thymidine Incorporation Proliferation Assay—Splenic
CD8 T-cells were purified using a Miltenyi MACS CD8 iso-
lation kit (90% purity) and cultured at 10:1 with bone mar-
row-derived dendritic cells with the LYLVCGERGF (G9GF),
LYLVCGERG (G9G), or LYLVCGERV (G9V) peptide in RPMI
medium supplemented with 5% FCS, 2 mM L-glutamine, 0.05
mM 2-mercaptoethanol, penicillin/streptomycin. Each sample
was plated in duplicate. After 48 h of incubation, cells were
pulsed with 0.5 Ci of [3H]thymidine for 18 h, harvested, and
counted to determine [3H]thymidine incorporation.
ELISAs for Chemokine and Cytokine Production—Superna-
tants were removed from the proliferation assay cultures prior
to the addition of [3H]thymidine. MIP1 was measured by
sandwich ELISA (R&D systems), whereas IFN was measured
using a similar protocol (BDBiosciences) with themodification
that the capture antibody was diluted in carbonate buffer and
incubated at 4 °C overnight. Plateswere blocked at 37 °C for 1 h,
and the detection antibody was incubated for 1 h at room
temperature.
Staining of Insulin-specific CD8 T-cells with H-2KdPeptide
Tetramers—Splenocytes from 6-week-old G9C/ NOD
micewere isolated, and red cells were lysed. 1 106 splenocytes
were then preincubatedwith 50 nM dasatinib (AxonMedchem)
for 30 min at 37 °C, and cells were washed in PBS with 2% FCS
and stained for 15 min at 37 °C using 0.5 g of each of the
H-2Kdpeptide tetramers (National Institutes of Health
tetramer facility): AYAAAAAAV (negative control), G9GF,
G9G, or G9V. Cells were then washed again prior to the addi-
tion ofCD8FITC (clone 53-6.7, BDBiosciences), CD4PE-Cy7
(clone RM4-5, eBioscience), CD19 PerCpCy5.5 (clone 1D3,
eBioscience), CD11b BV421 (clone M1/70, Biolegend) and
checked for viability using an eFluor 780 viability dye (eBiosci-
ence). Cells were incubated at 4 °C for 30 min prior to washing
again before acquisition on a BD Biosciences FACSCanto II,
with data analyzed with Flowjo version 7.6.5 software (Trees-
tar) gating on Live CD8CD19CD11bCD4Tetramer T-
cells. The mean fluorescence intensity was then calculated and
further analyzed using GraphPad Prism version 4 software.
Construct Design—The TCR and - chains and the H-2Kd
heavy chains (tagged and untagged with a biotinylation se-
quence) and the human 2m chain were generated by PCR
mutagenesis (Stratagene) and PCR cloning. All sequences were
confirmed by automated DNA sequencing (Lark Technolo-
gies). The G9C8 TCR and - chains, the H-2Kd heavy chains
(residues 1–248) (1, 2, and 3 domains), and 2m (residues
1–100) were also cloned. G9C8TCR and - chains, theH-2Kd
 chains, and 2m sequences were inserted into separate
pGMT7 expression plasmids under the control of the T7 pro-
moter (35).
Protein Expression, Refolding, and Purification—Competent
Rosetta DE3 Escherichia coli cells were used to produce the
G9C8TCR and - chains, theH-2Kdheavy chains, and2m in
the form of inclusion bodies using 0.5 mM isopropyl 1-thio--
D-galactopyranoside to induce expression, and proteins were
chemically refolded as described previously (36).
pMHCI Biotinylation—Biotinylated pMHCI was prepared as
described previously (37).
pMHC Stability Assays—Thermal stability of H-2Kd com-
plexes was assessed by circular dichroism (CD) spectroscopy,
monitoring the change in ellipticities at 218 nm. Data were
collected on an Aviv Model 215 spectropolarimeter (Aviv Bio-
medical Inc., Lakewood,NJ) using a 0.1-cmquartz cell. Proteins
were dissolved in PBS at concentrations of 2.5 M. Melting
curves were recorded in 0.5 °C intervals from 4 °C up to a max-
imum temperature of 90 °C when protein aggregation was
observed. Melting curves were analyzed assuming a two-state
trimer-to-monomer transition from the native (N) to unfolded
(U) conformation N37 3U with an equilibrium constant K 
[U]3/[N3]  F/(3c2(1  F)3), where F and c are the degree of
folding and protein concentration, respectively. Data were fit-
ted as described (38). Fitted parameters were the melting tem-
perature (Tm), van’t Hoff’s enthalpy (HvH), and the slope and
intercept of the native baseline. Because all protein complexes
aggregated upon unfolding, the ellipticity of the unfolded state
was set as a constant of4,500 degrees cm2 dmol1 (39, 40).
Surface Plasmon Resonance Analysis—Binding analysis was
performed using a BIAcore 3000TM equipped with a CM5 sen-
sor chip as described previously (41). Binding analysis was per-
formed four times in independent experiments using pMHC
monomers generated in house and from theNational Institutes
of Health tetramer facility. Approximately 200–500 RU of pep-
tide-H-2Kd (in complex with G9GF, G9G, or G9V) was
attached to theCM5 sensor chip at a slow flow rate of 10l/min
to ensure uniform distribution on the chip surface. Combined
with the small amount of peptide-H-2Kd bound to the chip
surface, this reduced the likelihood of off-rate-limiting mass
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transfer effects. The G9C8 TCR was purified and concentrated
to 140 M on the same day of surface plasmon resonance
analysis to reduce the likelihood of TCR aggregation affecting
the results. For equilibrium analysis, eight serial dilutions were
prepared in triplicate for each sample and injected over the
relevant sensor chips at 25 °C. TCR was injected over the chip
surface using kinetic injections at a flow rate of 45l/min using
H-2KdAYAAAAAAVorHLA-A*0201ALWGPDPAAA in dif-
ferent experiments as negative controls.
Crystallization, Diffraction Data Collection, and Model
Refinement—All protein crystals were grown at 18 °C by vapor
diffusion via the sitting drop technique. 200 nl of each pMHCI
(10mg/ml) in crystallization buffer (10mMTris, pH 8.1, and 10
mM NaCl) was added to 200 nl of reservoir solution. H2Kd-
G9GF crystals were grown in 4% PEG 4000, 0.1 M sodium ace-
tate, pH 4.6, H-2KdG9G crystals were grown in 20% PEG 3350,
0.2 M sodium malonate, 0.1 M Bistris propane, pH 6.5, and
H-2KdG9V crystals were grown in 20% PEG 6000, 0.2 M cal-
cium chloride, 0.1 M Tris propane, pH 8.0 (42). All crystals were
soaked in 30% ethylene glycol before cryo-cooling. All crystal-
lization screens and optimization experiments were completed
using anArt-Robbins Phoenix dispensing robot (Alpha Biotech
Ltd., UK). Data were collected at 100 K at the Diamond Light
Source (Oxfordshire, UK). All data sets were collected at a
wavelength of 0.98 Å using an ADSC Q315 CCD detector.
Reflection intensities were estimated with the XIA2 package
(43), and the data were scaled, reduced, and analyzed with
SCALA and the CCP4 package (44). Structures were solved
with molecular replacement using PHASER (45). Sequences
were adjusted with COOT (46), and the models were refined
with REFMAC5.Graphical representations were preparedwith
PyMOL (47). The reflection data and final model coordinates
were deposited in the Protein Data Bank (H-2KdG9GF, code
4Z78; H-2KdG9G, code 4WDI; and H-2KdG9V, code 4Z76).
Results
Insulin-reactive CD8 T-cells Are Stimulated by Native and
Altered Insulin Peptides—We have previously demonstrated
that the G9C8 T-cell clone can induce rapid onset T1D in
NOD.scidmice (24). This pathology is governed by the ability of
G9C8 T-cells to recognize a region of the insulin B chain pro-
tein that is conserved between humans and mice and is an
autoantigen in both species (26, 33, 34). The G9C8 T-cell clone
recognized both the native 9-mer (G9G) and native 10-mer
(G9GF) versions of this peptide but generated a stronger
response (proliferation, MIP1, and IFN production) to the
G9G peptide compared with the G9GF peptide (Fig. 1). The
G9C8T-cell clone was about 5 timesmore sensitive to the G9G
peptide compared with G9GF in all assays. Interestingly, sub-
stitution of Gly for Val at residue 9 in the G9V peptide, distal
from the central bulge of the peptide that is usually involved in
TCR contacts, increased activation markedly compared with
the G9G peptide (the G9C8 T-cell clone was at least 5 times
more sensitive to G9V compared with G9G in all assays) (Fig.
1). These observations warranted further investigation of the
molecular rules that govern recognition of this important
autoantigen during T1D.
Recognition of the Native G9G Peptide Is Characterized by
Weak TCR Binding—We investigated the molecular interac-
tion between the G9C8 TCR and the different peptide ligands
by performing tetramer staining experiments. Although the
G9GF peptide induced a low level of T-cell activation, the
H-2KdG9GF tetramers did not robustly stain the G9C8 T-cell
clone (Fig. 2A). The H-2KdG9V tetramer stained 87.9% of the
G9C8 clone, in line with the strong activation observed with
this ligand (Fig. 2A). Although theH-2KdG9G tetramer stained
more weakly compared with H-2KdG9V, consistent with the
T-cell activation analysis, the level of staining was still high
(85.7% G9C8 clone staining). The biggest difference between
the H-2KdG9G and H-2KdG9V tetramers was the mean fluo-
rescence intensity, being substantially higher for H-2KdG9V
(Fig. 2B). In order to further examine the strong staining of the
H-2KdG9G tetramer compared with H-2KdG9GF, we deter-
mined the thermal stability of the soluble pMHCproteins using
CD spectroscopy. Consistent with our previous findings (32),
the lack of an optimal anchor at theC terminus of theG9GF and
G9G peptides had a large negative effect on their stability com-
pared with G9V, which showed a melting temperature over
20 °C higher than G9G and G9GF (Fig. 2C). Similar observa-
tions from other groups have been reported in whichmodifica-
tion of the N-terminal positions of a melanoma peptide
increased pMHC stability and immunogenicity (48). The simi-
larly low thermal stability of bothG9GF andG9Gdid not reveal
an obvious mechanism for the high level of H-2KdG9G
tetramer staining comparedwithH-2KdG9GF, althoughG9GF
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FIGURE 1. T-cell functional assays. Purified insulin-reactive CD8 T-cells
were incubated for 72 h with native 10-mer peptide, LYLVCGERGF (G9GF),
native 9-mer peptide, LYLVCGERG (G9G), or heteroclitic peptide, LYLVCGERV
(G9V), togetherwithbonemarrow-deriveddendritic cells. [3H]Thymidinewas
added, and incorporation was measured upon harvesting 18 h later and
counting on a micro--counter to measure T-cell proliferation (A). Superna-
tants from the cultures were removed prior to the addition of [3H]thymidine
and used to measure MIP1 (B) and IFN (C) by ELISA.
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was slightly less stable than G9G overall. Thus, we performed
surface plasmon resonance (Fig. 2,D and E) using recombinant
soluble G9C8 TCR (Fig. 3) injected over a sensor chip coated
with H-2KdG9GF, H-2KdG9G, and H-2KdG9V. The G9C8
TCRbound to the non-nativeH-2KdG9Vwith a comparatively
strong affinity (KD  13.6 M). This was in contrast to the
weaker binding affinity to the native G9GF and G9G peptides
(KD 113 and 286 M, respectively), mirroring the effect on
TCR affinity by altering peptide anchor residues reported
before (49, 50). These data further confounded the enhanced
T-cell activation and tetramer staining of the G9G peptide
compared with G9GF, because the G9C8 TCR bound to
FIGURE 2. Molecular characterization of G9C8 T-cell antigen recognition. A, staining of insulin-reactive CD8 T-cells with peptide-tetramer complexes.
Purified insulin-reactive CD8 T-cells from the NOD mouse were incubated with H-2KdAYAAAAAAV negative control tetramer, H-2KdG9GF tetramer,
H-2KdG9G tetramer, andH-2KdG9V tetramer, followedby anti-CD8monoclonal antibody, and analyzed by flow cytometry. B, themean fluorescence intensity
of the tetramer staining is shown for different concentrations of each tetramer. C, CD thermal denaturation curves recorded at 218 nm are shown for selected
pMHC samples.Dots, measured values fitted assuming a two-state trimer-to-monomer transition as described under “Experimental Procedures.” The panel to
the right shows bar graphs of the thermal stability with respect to melting temperature (top) and van’t Hoff’s enthalpy of unfolding (bottom). D–F, binding
affinity of theG9C8 TCR interaction at 25 °C. Eight serial dilutions of theG9C8 TCRweremeasured; representative data from four independent experiments are
plotted. Binding analysis was performed using pMHCmonomers generated in house and from the National Institutes of Health tetramer facility. The equilib-
rium binding constant KD values were calculated using a nonlinear curve fit (y  (P1x)/P2  x); mean plus S.D. values are shown. In order to calculate each
response, the G9C8 TCR was also injected over a control sample (H-2KdAYAAAAAAV or HLA-A*0201-ALWGPDPAAA in different experiments) that was
deducted from the experimental data (shown in the inset). D, G9C8 versus H-2KdG9GF. E, G9C8 versus H-2KdG9G. F, G9C8 versus H-2KdG9V.
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H-2KdG9GFwithmore than 2-fold stronger affinity compared
with H-2KdG9G. However, because the G9GF and G9G pep-
tides formed relatively unstable pMHC complexes and because
the TCR affinity was weak, these affinities should be considered
reproducible estimates rather than absolute values. As such, the
tetramer staining and T-cell activation assays probably repre-
sent a more accurate comparative estimation of the affinity dif-
ferences between the G9C8 TCR and the G9G/G9GF peptides.
Peptide Residues Glu-7 and Arg-8 Extend Out of the MHC
Binding Groove for Potential TCR Contact—In order to further
understand the mechanism underlying the weak affinity
between the G9C8 TCR and H-2KdG9G, we solved the crystal
structures of H-2KdG9GF, H-2KdG9G, and H-2KdG9V.
H-2KdG9G crystallized in space group P1, and H-2KdG9V
crystallized in two distinct space groups, P1 and P1 21 1 (only
the P1 data set is shown here in detail), which showed identical
features (data not shown). H-2KdG9GF crystallized in space
group P 21 21 21with three copies in the asymmetric unit (omit
maps and density plots are shown in Fig. 4). All structures were
determined to resolutions between 1.9 and 2.3 Å with crystal-
lographic Rwork/Rfree ratios within accepted limits as shown in
the theoretically expected distribution (51) (Table 1). Align-
ment of the three structures generated routemean square devi-
ation values of 0.491 (G9G versus G9GF), 0.355 (G9G versus
G9V), and 0.647 (G9V versus G9GF), demonstrating that the
overall conformation of all of the structures was very similar.
The G9G and G9V structures featured unambiguous density
around the peptides (Fig. 4, A and B), which were presented in
an extended conformation, primarily anchored at peptide resi-
dues 2 and 9, with Cys-5 acting as a secondary anchor in the
center of the peptide and residues 6–8 extending away from
the groove (Fig. 5, A and B). For G9GF, clear electron density
was only observed for peptide residues 1–4 (Fig. 4C), indicating
flexibility in the rest of the peptide. Indeed, although all three
copies were identical at the N-terminal end of the peptide, in
copies 1 and 2, the peptide appeared to be anchored mainly at
position 9, with position 10 extending out toward the end of the
MHC groove and performing a secondary anchoring role
(G9GF-stretched) (Fig. 4C). In copy 3, the peptide appeared to
be anchored at position 10 (G9GF-bulged) (Fig. 4C). Although
unambiguous density was not observed for peptide residues
5–8 in theH-2KdG9GF structure, these residuesweremodeled
in the same position and orientation as in the H-2KdG9G and
G9V structures, guided by agreement with the final model,
which indicated no negative density for these residues in this
conformation. The solvent-exposed nature of peptide residues
1, 4, 6, and 7 in the H-2KdG9G and G9V structures (and pos-
sibly the G9GF structure) makes them the most likely TCR
contact residues, supported by our previous data showing
that modifications at peptide residues 1, 4, 6 (residue 6 could
affect the conformation of residue 7), and 8 reduced T-cell
recognition and could act as antagonists (32, 52). It is less
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and copy 3 is light purple. Note that the observed density (marine blue), has
positive difference density close to the half-occupancy residues 4–10 and
little negative density in the same region. The obvious disorder in the C-ter-
minal 7 residues of the peptides does not extend to Tyr-84 in any of the
copies.
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likely that modification of these residues would affect pep-
tide stability because of their apparent minimal role as
anchor residues.
Interactions between the Peptide C Terminus and the MHC
Binding Groove Determine pMHC Stability—We next investi-
gated the interactions between the different peptides and
H-2Kd (Table 2). G9G made 17 vdWs and 4 HBs (Fig. 6C), and
G9Vmade 21 vdWs and 4 HBs (Fig. 6D), both through peptide
residue 9. Although G9G only lost four vdW contacts with
anchor residue Gly-9 compared with G9V (anchor residue Val-
9), there were knock-on effects at the N terminus of the peptide
(Table 2). The first 5 residues of G9V made 102 vdWs and 12
HBs with theMHC binding groove, whereas the first 5 residues
of G9G only made 102 vdWs and 9HBs (Table 2). These obser-
vations demonstrate the importance of optimal anchoring at
both the N and C terminus of the peptide and help explain the
substantially lower thermal stability of the G9G andG9GF pep-
tides compared with G9V (Fig. 2C).
The dynamic nature of the G9GF peptide, evident from the
lack of electron density for the central and C-terminal portion
of the peptide, made analysis of peptide-MHC contacts unreli-
able. However, this instability, presumably mediated by the
extra residue in the G9GF peptide, could contribute toward the
lower relative stability of the H-2KdG9GF protein as well as
altering interactions with the G9C8 TCR.
Tyr-84 in the MHC 1 Domain Swings Open Possibly to
Enable Unusual Presentation of the G9GF Peptide—We ex-
pected that the additional residue at the C terminus in the
G9GF peptide compared with G9G would require the central
portion of the G9GF peptide to bulge further out of the groove
to accommodate the extra residue, forcing G9GF into a com-
pletely different conformation compared with G9G, as is usu-
ally seen with longer MHCI-restricted peptides (53–55).
Although the electron density was not definitive, our analysis
indicated that the G9GF-bulgedmodel anchored at position 10
mediating a slightly different conformation around peptide res-
idues 6–8. However, in the more dominant conformation
observed in the other two copies in the asymmetric unit (G9GF-
stretched), the C terminus of theMHC 1 helix flexed by 1.8 Å,
allowing Phe-10 to slide further down into the opening of the
TABLE 1
Data collection and refinement statistics for pMHC structures
One crystal was used for solving each structure. Values in parenthesis refer to the highest resolution shell. Root mean square deviation targets are automatically assigned by
REFMAC5 according to the appropriate level based on the maximum likelihood method: 0.019 Å for bond lengths and 1.94° for bond angles. r.m.s., root mean square.
H-2KdG9GF H-2KdG9G H-2KdG9V
Protein Data Bank code 4Z78 4WDI 4Z76
Data collection
Space group P21 21 21 P1 P1
Cell dimensions
a, b, c (Å) 46.2, 151.6, 182.2 46.9, 62.7, 72.7 48.0, 62.4, 72.3
, ,  (degrees) 90, 90, 90 68.1, 85.8, 85.2 69.8, 85.8, 87.1
Resolution (Å) 37.1-2.3 29.5-2.3 38.3-1.9
Rmerge (%) 12.7 (92.9) 6.8 (35.1) 5.7 (27.2)
Mean I/I 10.4 (3.0) 8.6 (92.0) 8.6 (2.0)
Completeness (%) 100.0 (100.0) 90.2 (91.5) 89.9 (89.9)
Redundancy 7.2 (7.3) 2.1 (2.2) 2.1 (2.2)
Refinement
Resolution (Å) 2.3 (2.36-2.30) 2.3 (2.37-2.31) 1.9 (1.93-1.88)
No. of reflections 57,725 (4,165) 28,604 (2,261) 54,089 (4,245)
No. of reflections in Rfree set 2,925 1,527 2,886
Rwork/Rfree 18.8/23.3 20.6/28.3 18.6/22.9
Mean B value (Å2) 39.8 37.9 27.8
Overall coordinate error (Å) 0.174 0.235 0.191
r.m.s. deviations
Bond lengths (Å) 0.015 0.016 0.015
Bond angles (degrees) 1.744 1.598 1.773
L Y L V C G E R(G/V)
Glu7 Arg8
Gly9
Val9
Thr80
Lys146
Thr143
Tyr123Phe95
Tyr84
Ser77
Thr80
Lys146
Thr143
Tyr84
H2-Kd α1
α1α2
α1
α1
α2
F-pocket
α2
F-pocket
G9G
G9V
A B
C
D
FIGURE 5. Interactions between the peptide C terminus and the MHC
binding groove determine pMHC stability. A, superposition of the G9G
peptide (magenta sticks) andG9Vpeptide (green sticks). TheH-2Kd1domain
is shown in a gray schematic. Arrows below the peptides indicate whether
each residue is positioned away from the binding groove for potential TCR
contact (up arrow), a primary or secondary anchor (down arrow), or in
between (no arrow). B, peptide residues Glu-7 and Arg-8 (magenta sticks)
bulge furthest away from theMHC groove (gray schematic). C, H-2Kd binding
groove is shown in a gray surface representation demonstrating the extended
conformation of the G9G peptide (magenta sticks). Right, the interactions
between the C terminus of the G9G peptide (magenta sticks) and the MHC
F-pocket (gray sticks). D, the H-2Kd binding groove is shown in a gray surface
representationdemonstrating theextendedconformationof theG9Vpeptide
(green sticks). Right, interactions between the C terminus of the G9V peptide
(green sticks) and the MHC F-pocket (gray sticks).
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groove (Fig. 6A). Additionally, MHC residue Tyr-84 side chain
underwent a largemovement of 8.2 Å to swing out of the way of
Phe-10, compared with its position in the G9GF-bulged, G9G,
andG9V structures (Fig. 6B). Thesemovements also altered the
shape of the MHC F-pocket. Tyr-84 made three vdWs and one
HB with the peptide in the G9G structure (Fig. 6C) but in that
position would cause a steric clash with Phe-10 in the G9GF
structure (Fig. 6D). In its alternative position in the G9GF-
stretched structure, Tyr-84 could potentially form stabilizing
interactions, including CH- ( edge-to-face) interactions (56)
with Phe-10, known to be important for peptide-MHC binding
(48). Thus, the dynamic movement by Tyr-84 in the G9GF-
stretched structuremight allowPhe-10 to be accommodated by
theMHC F-pocket (Fig. 6E) rather than forming a more prom-
inent central bulge, observed in most other MHCI structures
with longer (9 residues) peptides.
Discussion
The NOD mouse model of T1D is an important tool for
investigating the role of T-cells in the destruction of islet-cells
in the pancreas. Other molecular investigations of T-cell-in-
duced autoimmunity have shed light on the selection andmode
of action of autoreactive T-cells. For example, we have recently
demonstrated that a preproinsulin-specific human TCR
derived fromaCD8T-cell boundwith extremelyweak affinity
and a highly focused binding footprint (5). Other studies of
autoreactive T-cells in other disease models have also demon-
strated suboptimal TCR binding, either through weak TCR
affinity (20), poor pMHC stability (18), topologically unusual
TCR binding (19, 20), or a combination (5, 20). These observa-
tions have led to the suggestion that autoreactiveT-cells receive
weak or unconventional signals in the thymus that lead to pos-
itive selection rather than deletion. Here, we show that the
G9C8T-cell clone is reactive to an autoantigenic peptide that is
part of the insulin protein but that the native epitopeswere both
relatively unstable compared with a heteroclitic peptide with
optimal anchor residues. The TCR from this clone bound with
weak affinity to the native epitopes, resulting in lower func-
tional avidity. This combination adds support to the notion that
selection of this clone could occur through weak T-cell signal-
ing in the thymus. T-cells that have high affinity TCRs formore
stable insulin-derived epitopes would probably be deleted
through negative selection, explaining their absence in the
periphery. The high levels of insulin expressed by -cells and
the probable high levels of G9G/G9GF epitopes on the surface
of these cells might bridge the activation threshold of G9C8-
like T-cells, inducing the autoreactivity observed. Surprisingly,
despite a weak monomeric affinity for the G9C8 TCR, H-2Kd
G9G tetramers could still robustly identify cognate T-cells. It is
possible that the comparatively strong murine pMHC-CD8
affinity, comparedwith human pMHC-CD8 (57, 58), could play
a role in stabilizing this weak affinity interaction at the cell
surface (59, 60). Importantly, the G9C8 T-cell did not express
an inherently weak binding TCR, because peptide substitution
of Gly to Val at position 9 resulted in anti-viral-like affinity (10,
12, 13). The corresponding enhanced tetramer staining using
the G9V peptide paves the way for the development of
improved reagents to isolate, phenotype, and clonotype insu-
lin-reactive CD8 T-cells to better follow and determine their
role in disease progression. Furthermore, this demonstration
that the G9C8 TCR could bind to an altered ligand with 10
times higher affinity comparedwith the native ligands opens up
the intriguing possibility that this T-cell clone could potentially
be primed by a more immunogenic target and then cross-react
with insulin B chain epitopes expressed by -cells through a
molecular mimicry type mechanism. Thus, this altered ligand
could also be used to test the potential role of molecular mim-
icry on disease outcome.
The stability of the pMHC complex is critical in the presen-
tation of epitopes to T-cells, because unstable pMHC will be
TABLE 2
Peptide-MHC contact table
SB, salt bridge; BSA, buried surface area between the peptide and MHC; r.m.s.
deviation, root mean square deviation calculated by aligning each pMHC complex
(-chain, peptide, and 2m) in PyMOL. A 3.4 Å cut-off was used for HBs and salt
bridges, and a 4 Å cut-off was used for vdWs.
Peptide
H-2KdG9G H-2KdG9V
vdW HB/SB vdW HB/SB
Leu-1 27 2 28 3
Tyr-2 21 3 24 5
Leu-3 18 2 19 2
Val-4 13 1 12 1
Cys-5 25 1 19 1
Gly-6 6 2 6 2
Glu-7 12 3 14 3
Arg-8 19 1 18 1
Gly/Val-9 17 4 21 4
Total 158 19 161 22
BSA (Å2) 1,909.4 1,983.4
r.m.s. deviation G9G/G9V 0.355 G9V/G9GF 0.647
G9G/G9GF 0.491
Gly9
Tyr84 Tyr84
A B
C D E
Phe10
Tyr84
Tyr84
α1 G9G
Tyr84
G9GF
FIGURE 6. MHC “opens the back door” to accommodate the extra C-ter-
minal residue in the G9GF peptide. A, superposition of the G9G peptide
(magenta sticks) and the G9GF peptide (yellow sticks) showing the extended
positionof theG9GF-stretchedC terminus and themovement in theH-2Kd1
domain (G9G (gray schematic) and G9GF (yellow schematic)). B, MHC residue
Tyr-84 “swings” 8.2 Å in G9GF-stretched (yellow sticks) complex compared
with the G9G (gray sticks) complex. C, interaction between G9G residue Gly-9
(magenta sticks) and MHC residue Tyr-84 (gray sticks). D, MHC residue Tyr-84
would cause a steric clash with G9GF residue Phe-10 (yellow sticks) when
positioned as in the G9G complex structure. E, interaction between G9GF
residue Phe-10 (yellow sticks) and MHC residue Tyr-84 (yellow sticks).
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present at lower concentrations or absent on the surface of
antigen-presenting cells. To confound this issue, previously (49,
61, 62) and here, we found that modifications that altered
pMHC stability also had a large effect on TCR binding affinity.
H-2Kd is unusual compared with the binding motif for most
othermouse alleles (that have an anchor at position 5 and the C
terminus) in that it anchors at positions 2 and the C terminus,
reminiscent of most human peptide-MHC binding motifs.
Thus, our observations concerning the effects of TCR binding
affinity upon altering the C-terminal anchor could be unique to
this murine MHC allele. Because the peptide modifications
were located at the C terminus, and the most solvent exposed
peptide residues were Glu-7 and Arg-8, it is reasonable to spec-
ulate that the G9C8 TCR focuses on the C terminus of the
peptide. This is consistent with our previous data demonstrat-
ing that modification of these residues (particularly Arg-8),
along with Val-4, which was also pointing out of the groove
according to our structural analysis, reduced T-cell activation
(32, 52). This observation could explain the strong binding
affinity between the G9C8 TCR and G9V, because Val-9 might
stabilize the main TCR-peptide contact region, enabling more
optimal contacts. Binding to this region of the peptidemay also
explain why, although the G9C8 TCR bound with a similarly
weak affinity to H-2KdG9G andH-2KdG9GF, the G9C8 T-cell
was more sensitive to the G9G peptide. The unusual presenta-
tionmode of theG9GF peptidemay affect the dynamics of TCR
binding, perhaps altering the formation of an optimal immune
synapse or inhibiting the formation of TCR catch bonds that
have recently been shown to play an important role in T-cell
activation (11).
Our structural investigations also revealed a novel and unex-
pected mode of peptide presentation that has far reaching
implications for T-cell antigen recognition in general. Al-
though structures of different length versions of the same pep-
tide have been published before, this is the first example in
which the peptide alters the shape of theMHCI binding groove
to accommodate an extra residue in the F-pocket. Additional
residues at the N terminus and C terminus have been shown to
have the following effects: 1) the central bulge of the peptide
was altered because the extra residue could not be accommo-
dated by the closedN-terminal end of theMHCbinding groove
(53–55); 2) the 9-mer version of the peptide assumed the same
conformation as the 10-mer version of the peptide by using
peptide residue 1, rather than residue 2, as the anchor (63); or 3)
extra residues protruded from the groove at the peptide termini
(64, 65). Here, the C-terminal end of the 10-mer G9GF peptide
formed a dynamic interaction with the MHC binding groove.
H-2KdG9GF crystallizedwith threemolecules in the asymmet-
ric unit, demonstrating two distinct conformations. The dom-
inant conformation observed in two of the copies (G9GF-
stretched) forced the MHC binding groove to open to
accommodate the bulky side chain of Phe-10, resulting inMHC
residue Tyr-84 swinging 8.2 Å and altering the shape of the
MHC F-pocket. Usually, the central residues of longer peptides
are squeezed intomore extended conformations because of the
closed nature of the MHCI binding groove, as observed in the
G9GF-bulged model of the structure. In the G9GF-stretched
structure, the movement around the MHC F-pocket enabled
the C terminus of the G9GF peptide to slide further down the
groove so that the N terminus of the peptide could adopt a
potentially similar conformation to the G9G and G9V 9-mer
peptides. The ability of the G9GF 10-mer peptide to “mimic”
the conformation of the 9-mer peptides is likely to be an impor-
tant factor facilitating recognition of the G9GF peptide by the
G9C8 TCR. The dynamic nature of the MHC binding groove
was highly unexpected and adds to other studies in which a
distinctmovement in theMHChelices and/or peptide has been
observed (66, 67). Combined, these data provide important evi-
dence demonstrating the highly flexible nature of peptide pres-
entation byMHC. Interestingly, a previous study implemented
mutation of Arg-84 for Ala-84 for the stable generation of a
single chain pMHC (68). Our findings would suggest that this
mutation could have a substantial effect on the shape and
dynamics of theMHC F pocket, leading to potential changes in
peptide presentation. The flexibility we observed around the
F-pocket also has implications for so-calledTCR-pMHC “catch
bonds.” A recent study demonstrated that, under force, some
TCR and pMHC interactions can become stronger, resulting in
enhanced T-cell activation (11). The formation of catch bonds
suggests that the TCR, pMHC, or both undergo structural rear-
rangements when under force during binding at the cell sur-
face, explaining the increase in binding strength. Our data,
demonstrating the potential dynamic nature of the region
around the MHC F-pocket, fits well with the notion of catch
bond formation.
In summary, we show that insulin reactivity by aCD8T-cell
clone, known to induce T1D, is characterized by weak TCR
affinity to a highly unstable pMHC. The G9C8 TCRwas able to
bindmore strongly to a peptide altered at the C terminus, dem-
onstrating the potential of this T-cell clone to be triggered by a
more immunogenic target. This observation also suggests that
the interaction between the TCR and pMHC is likely to be
focused toward the C terminus of the peptide, explaining the
difference in sensitivity between the C-terminally altered pep-
tide ligands investigated. Finally, we demonstrate a novel mode
of flexible peptide presentation in which the MHC can effec-
tively “open the back door” to accommodate extra C-terminal
peptide residues.
Author Contributions—C. M., J. A. P., E. D. L., P. J. R., K. B., A. T.,
and D. K. C. performed experiments. P. J. R. and D. K. C. performed
the structural analysis. A. K. S., F. S. W., and D. K. C. conceived and
funded the study and wrote the manuscript.
Acknowledgments—We thank Professor DavidMargulies and Profes-
sor George Papadopoulos for critical reading of the manuscript. We
also thank the staff at Diamond Light Source for providing facilities
and support.
References
1. Bottazzo,G. F., Dean, B.M.,McNally, J.M.,MacKay, E.H., Swift, P.G., and
Gamble, D. R. (1985) In situ characterization of autoimmune phenomena
and expression of HLA molecules in the pancreas in diabetic insulitis.
N. Engl. J. Med. 313, 353–360
2. Willcox, A., Richardson, S. J., Bone, A. J., Foulis, A. K., and Morgan, N. G.
(2009) Analysis of islet inflammation in human type 1 diabetes. Clin. Exp.
Immunol. 155, 173–181
Flexible Peptide-MHC Binding of a T1D Epitope
JULY 31, 2015•VOLUME 290•NUMBER 31 JOURNAL OF BIOLOGICAL CHEMISTRY 18931
 at U
N
IV
 W
A
LES CO
LL O
F CA
RD
IF on A
ugust 18, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
3. Nejentsev, S., Howson, J. M., Walker, N. M., Szeszko, J., Field, S. F., Ste-
vens, H. E., Reynolds, P., Hardy, M., King, E., Masters, J., Hulme, J., Maier,
L. M., Smyth, D., Bailey, R., Cooper, J. D., Ribas, G., Campbell, R. D.,
Clayton, D.G., Todd, J. A., andWellcomeTrust CaseControl Consortium
(2007) Localization of type 1 diabetes susceptibility to the MHC class I
genes HLA-B and HLA-A. Nature 450, 887–892
4. Vizler, C., Bercovici, N., Cornet, A., Cambouris, C., and Liblau, R. S. (1999)
Role of autoreactive CD8T cells in organ-specific autoimmune diseases:
insight from transgenic mouse models. Immunol. Rev. 169, 81–92
5. Bulek, A. M., Cole, D. K., Skowera, A., Dolton, G., Gras, S., Madura, F.,
Fuller, A.,Miles, J. J., Gostick, E., Price, D. A., Drijfhout, J.W., Knight, R. R.,
Huang, G. C., Lissin, N., Molloy, P. E., Wooldridge, L., Jakobsen, B. K.,
Rossjohn, J., Peakman, M., Rizkallah, P. J., and Sewell, A. K. (2012) Struc-
tural basis for the killing of human beta cells by CD8() T cells in type 1
diabetes. Nat. Immunol. 13, 283–289
6. Skowera, A., Ellis, R. J., Varela-Calviño, R., Arif, S., Huang, G. C., Van-
Krinks, C., Zaremba, A., Rackham, C., Allen, J. S., Tree, T. I. M., Zhao, M.,
Dayan, C. M., Sewell, A. K., Unger, W. W., Unger, W., Drijfhout, J. W.,
Ossendorp, F., Roep, B. O., and Peakman, M. (2008) CTLs are targeted to
kill beta cells in patients with type 1 diabetes through recognition of a
glucose-regulated preproinsulin epitope. J. Clin. Invest. 118, 3390–3402
7. Coppieters, K. T., Dotta, F., Amirian, N., Campbell, P. D., Kay, T. W. H.,
Atkinson, M. A., Roep, B. O., and von Herrath, M. G. (2012) Demonstra-
tion of islet-autoreactive CD8 T cells in insulitic lesions from recent onset
and long-term type 1 diabetes patients. J. Exp. Med. 209, 51–60
8. Wong, F. S., Karttunen, J., Dumont, C., Wen, L., Visintin, I., Pilip, I. M.,
Shastri, N., Pamer, E. G., and Janeway, C. A. (1999) Identification of an
MHC class I-restricted autoantigen in type 1 diabetes by screening an
organ-specific cDNA library. Nat. Med. 5, 1026–1031
9. Kronenberg, D., Knight, R. R., Estorninho, M., Ellis, R. J., Kester, M. G., de
Ru, A., Eichmann, M., Huang, G. C., Powrie, J., Dayan, C. M., Skowera, A.,
van Veelen, P. A., and Peakman, M. (2012) Circulating preproinsulin sig-
nal peptide-specific CD8 T cells restricted by the susceptibility molecule
HLA-A24 are expanded at onset of type 1 diabetes and kill -cells.Diabe-
tes 61, 1752–1759
10. Bridgeman, J. S., Sewell, A. K., Miles, J. J., Price, D. A., and Cole, D. K.
(2012) Structural and biophysical determinants of  T-cell antigen rec-
ognition. Immunology 135, 9–18
11. Liu, B., Chen, W., Evavold, B. D., and Zhu, C. (2014) Accumulation of
dynamic catch bonds between TCR and agonist peptide-MHC triggers T
cell signaling. Cell 157, 357–368
12. Cole, D. K., Pumphrey, N. J., Boulter, J. M., Sami, M., Bell, J. I., Gostick, E.,
Price, D. A., Gao, G. F., Sewell, A. K., and Jakobsen, B. K. (2007) Human
TCR-binding affinity is governed by MHC class restriction. J. Immunol.
178, 5727–5734
13. Aleksic, M., Liddy, N., Molloy, P. E., Pumphrey, N., Vuidepot, A., Chang,
K.-M., and Jakobsen, B. K. (2012) Different affinity windows for virus and
cancer-specific T-cell receptors: implications for therapeutic strategies.
Eur. J. Immunol. 42, 3174–3179
14. Miles, K. M., Miles, J. J., Madura, F., Sewell, A. K., and Cole, D. K. (2011)
Real time detection of peptide-MHC dissociation reveals that improve-
ment of primary MHC-binding residues can have a minimal, or no, effect
on stability.Mol. Immunol. 48, 728–732
15. Ekeruche-Makinde, J., Clement, M., Cole, D. K., Edwards, E. S. J., Ladell,
K., Miles, J. J., Matthews, K. K., Fuller, A., Lloyd, K. A., Madura, F., Dolton,
G. M., Pentier, J., Lissina, A., Gostick, E., Baxter, T. K., Baker, B. M., Riz-
kallah, P. J., Price, D. A., Wooldridge, L., and Sewell, A. K. (2012) T-cell
receptor-optimized peptide skewing of the T-cell repertoire can enhance
antigen targeting. J. Biol. Chem. 287, 37269–37281
16. Rosenberg, S. A., Yang, J. C., and Restifo, N. P. (2004) Cancer immuno-
therapy: moving beyond current vaccines. Nat. Med. 10, 909–915
17. Li, Y., Huang, Y., Lue, J., Quandt, J. A., Martin, R., and Mariuzza, R. A.
(2005) Structure of a human autoimmune TCR bound to a myelin basic
protein self-peptide and amultiple sclerosis-associatedMHC class II mol-
ecule. EMBO J. 24, 2968–2979
18. Yin, Y., Li, Y., Kerzic, M. C., Martin, R., and Mariuzza, R. A. (2011) Struc-
ture of a TCR with high affinity for self-antigen reveals basis for escape
from negative selection. EMBO J. 30, 1137–1148
19. Sethi, D. K., Schubert, D. A., Anders, A.-K., Heroux, A., Bonsor, D. A.,
Thomas, C. P., Sundberg, E. J., Pyrdol, J., andWucherpfennig, K.W. (2011)
A highly tilted binding mode by a self-reactive T cell receptor results in
altered engagement of peptide and MHC. J. Exp. Med. 208, 91–102
20. Hahn, M., Nicholson, M. J., Pyrdol, J., and Wucherpfennig, K. W. (2005)
Unconventional topology of self peptide-major histocompatibility com-
plex binding by a human autoimmune T cell receptor. Nat. Immunol. 6,
490–496
21. Maynard, J., Petersson, K., Wilson, D. H., Adams, E. J., Blondelle, S. E.,
Boulanger, M. J., Wilson, D. B., and Garcia, K. C. (2005) Structure of an
autoimmune T cell receptor complexed with class II peptide-MHC: in-
sights into MHC bias and antigen specificity. Immunity 22, 81–92
22. Rückert, C., Fiorillo, M. T., Loll, B., Moretti, R., Biesiadka, J., Saenger, W.,
Ziegler, A., Sorrentino, R., and Uchanska-Ziegler, B. (2006) Conforma-
tional dimorphism of self-peptides and molecular mimicry in a disease-
associated HLA-B27 subtype. J. Biol. Chem. 281, 2306–2316
23. Sandalova, T., Michaëlsson, J., Harris, R. A., Odeberg, J., Schneider, G.,
Kärre, K., and Achour, A. (2005) A structural basis for CD8 T cell-de-
pendent recognition of non-homologous peptide ligands: implications for
molecular mimicry in autoreactivity. J. Biol. Chem. 280, 27069–27075
24. Wong, F. S., Visintin, I., Wen, L., Flavell, R. A., and Janeway, C. A. (1996)
CD8T cell clones from young nonobese diabetic (NOD) islets can transfer
rapid onset of diabetes in NOD mice in the absence of CD4 cells. J. Exp.
Med. 183, 67–76
25. Wong, F. S., Visintin, I., Wen, L., Granata, J., Flavell, R., and Janeway, C. A.
(1998) The role of lymphocyte subsets in accelerated diabetes in nonobese
diabetic-rat insulin promoter-B7-1 (NOD-RIP-B7–1) mice. J. Exp. Med.
187, 1985–1993
26. Daniel, D., Gill, R. G., Schloot, N., andWegmann, D. (1995) Epitope spec-
ificity, cytokine production profile and diabetogenic activity of insulin-
specific T cell clones isolated from NOD mice. Eur. J. Immunol. 25,
1056–1062
27. Bettini, M., and Vignali, D. A. A. (2011) T cell-driven initiation and prop-
agation of autoimmune diabetes. Curr. Opin. Immunol. 23, 754–760
28. Jayasimhan, A.,Mansour, K. P., and Slattery, R.M. (2014) Advances in our
understanding of the pathophysiology of Type 1 diabetes: lessons from the
NOD mouse. Clin. Sci. 126, 1–18
29. Babad, J., Geliebter, A., and DiLorenzo, T. P. (2010) T-cell autoantigens in
the non-obese diabetic mouse model of autoimmune diabetes. Immunol-
ogy 131, 459–465
30. Wong, F. S., Siew, L. K., Scott, G., Thomas, I. J., Chapman, S., Viret, C., and
Wen, L. (2009) Activation of insulin-reactive CD8 T-cells for develop-
ment of autoimmune diabetes. Diabetes 58, 1156–1164
31. Nakayama, M., Abiru, N., Moriyama, H., Babaya, N., Liu, E., Miao, D., Yu,
L.,Wegmann, D. R., Hutton, J. C., Elliott, J. F., and Eisenbarth, G. S. (2005)
Prime role for an insulin epitope in the development of type 1 diabetes in
NOD mice. Nature 435, 220–223
32. Wong, F. S., Moustakas, A. K.,Wen, L., Papadopoulos, G. K., and Janeway,
C. A. (2002) Analysis of structure and function relationships of an autoan-
tigenic peptide of insulin bound to H-2K(d) that stimulates CD8 T cells in
insulin-dependent diabetes mellitus. Proc. Natl. Acad. Sci. U.S.A. 99,
5551–5556
33. Alleva, D. G., Crowe, P. D., Jin, L., Kwok, W.W., Ling, N., Gottschalk, M.,
Conlon, P. J., Gottlieb, P. A., Putnam, A. L., and Gaur, A. (2001) A disease-
associated cellular immune response in type 1 diabetics to an immu-
nodominant epitope of insulin. J. Clin. Invest. 107, 173–180
34. Alleva, D. G., Gaur, A., Jin, L., Wegmann, D., Gottlieb, P. A., Pahuja, A.,
Johnson, E. B., Motheral, T., Putnam, A., Crowe, P. D., Ling, N., Boehme,
S. A., and Conlon, P. J. (2002) Immunological characterization and thera-
peutic activity of an altered-peptide ligand, NBI-6024, based on the im-
munodominant type 1 diabetes autoantigen insulin B-chain (9–23) pep-
tide. Diabetes 51, 2126–2134
35. Garboczi, D. N., Hung, D. T., and Wiley, D. C. (1992) HLA-A2-peptide
complexes: refolding and crystallization of molecules expressed in Esche-
richia coli and complexed with single antigenic peptides. Proc. Natl. Acad.
Sci. U.S.A. 89, 3429–3433
36. Cole, D. K., Miles, K. M., Madura, F., Holland, C. J., Schauenburg, A. J.,
Godkin, A. J., Bulek, A. M., Fuller, A., Akpovwa, H. J. E., Pymm, P. G.,
Flexible Peptide-MHC Binding of a T1D Epitope
18932 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 290•NUMBER 31•JULY 31, 2015
 at U
N
IV
 W
A
LES CO
LL O
F CA
RD
IF on A
ugust 18, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Liddy, N., Sami,M., Li, Y., Rizkallah, P. J., Jakobsen, B. K., and Sewell, A. K.
(2014) T-cell receptor (TCR)-peptide specificity overrides affinity-en-
hancing TCR-major histocompatibility complex interactions. J. Biol.
Chem. 289, 628–638
37. Madura, F., Rizkallah, P. J.,Miles, K.M., Holland, C. J., Bulek, A.M., Fuller,
A., Schauenburg, A. J. A., Miles, J. J., Liddy, N., Sami, M., Li, Y., Hossain,
M., Baker, B.M., Jakobsen, B. K., Sewell, A. K., andCole, D. K. (2013) T-cell
receptor specificity maintained by altered thermodynamics. J. Biol. Chem.
288, 18766–18775
38. Greenfield, N. J. (2004) Analysis of circular dichroism data. Methods En-
zymol. 383, 282–317
39. Bouvier, M., and Wiley, D. C. (1994) Importance of peptide amino and
carboxyl termini to the stability of MHC class I molecules. Science 265,
398–402
40. Venyaminov, S. Y., Baikalov, I. A., Shen, Z. M., Wu, C. S., and Yang, J. T.
(1993) Circular dichroic analysis of denatured proteins: inclusion of dena-
tured proteins in the reference set. Anal. Biochem. 214, 17–24
41. Cole, D. K., Dunn, S. M., Sami, M., Boulter, J. M., Jakobsen, B. K., and
Sewell, A. K. (2008) T cell receptor engagement of peptide-major histo-
compatibility complex class I does not modify CD8 binding.Mol. Immu-
nol. 45, 2700–2709
42. Bulek, A. M., Madura, F., Fuller, A., Holland, C. J., Schauenburg, A. J. A.,
Sewell, A. K., Rizkallah, P. J., andCole, D. K. (2012)TCR/pMHCoptimized
protein crystallization screen. J. Immunol. Methods 382, 203–210
43. Winter, G., Lobley, C. M. C., and Prince, S. M. (2013) Decision making in
xia2. Acta Crystallogr. D Biol. Crystallogr. 69, 1260–1273
44. Collaborative Computational Project, Number 4 (1994) The CCP4 suite:
programs for protein crystallography.ActaCrystallogr. DBiol. Crystallogr.
50, 760–763
45. McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Sto-
roni, L. C., and Read, R. J. (2007) Phaser crystallographic software. J. Appl.
Crystallogr. 40, 658–674
46. Emsley, P., and Cowtan, K. (2004) Coot: model-building tools for molec-
ular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126–2132
47. DeLano, W. L. ( 2012) The PyMOL Molecular Graphics System, version
1.5.0.1, Schroedinger, LLC, New York
48. van Stipdonk, M. J. B., Badia-Martinez, D., Sluijter, M., Offringa, R., van
Hall, T., and Achour, A. (2009) Design of agonistic altered peptides for the
robust induction of CTL directed towards H-2Db in complex with the
melanoma-associated epitope gp100. Cancer Res. 69, 7784–7792
49. Cole, D. K., Edwards, E. S. J., Wynn, K. K., Clement, M., Miles, J. J., Ladell,
K., Ekeruche, J., Gostick, E., Adams, K. J., Skowera, A., Peakman, M.,
Wooldridge, L., Price, D.A., and Sewell, A. K. (2010)Modification ofMHC
anchor residues generates heteroclitic peptides that alter TCR binding
and T cell recognition. J. Immunol. 185, 2600–2610
50. Chen, J.-L., Stewart-Jones, G., Bossi, G., Lissin, N. M., Wooldridge, L.,
Choi, E. M. L., Held, G., Dunbar, P. R., Esnouf, R. M., Sami, M., Boulter,
J. M., Rizkallah, P., Renner, C., Sewell, A., van der Merwe, P. A., Jakobsen,
B. K., Griffiths, G., Jones, E. Y., and Cerundolo, V. (2005) Structural and
kinetic basis for heightened immunogenicity of T cell vaccines. J. Exp.
Med. 201, 1243–1255
51. Tickle, I. J., Laskowski, R. A., and Moss, D. S. (2000) Rfree and the rfree
ratio. II. Calculation Of the expected values and variances of cross-valida-
tion statistics in macromolecular least-squares refinement. Acta Crystal-
logr. D Biol. Crystallogr. 56, 442–450
52. Petrich de Marquesini, L. G., Moustakas, A. K., Thomas, I. J., Wen, L.,
Papadopoulos, G. K., andWong, F. S. (2008) Functional inhibition related
to structure of a highly potent insulin-specific CD8 T cell clone using
altered peptide ligands. Eur. J. Immunol. 38, 240–249
53. Tynan, F. E., Borg, N. A., Miles, J. J., Beddoe, T., El-Hassen, D., Silins, S. L.,
van Zuylen, W. J. M., Purcell, A. W., Kjer-Nielsen, L., McCluskey, J., Bur-
rows, S. R., and Rossjohn, J. (2005) High resolution structures of highly
bulged viral epitopes bound to major histocompatibility complex class I.
Implications for T-cell receptor engagement and T-cell immunodomi-
nance. J. Biol. Chem. 280, 23900–23909
54. Tynan, F. E., Burrows, S. R., Buckle, A. M., Clements, C. S., Borg, N. A.,
Miles, J. J., Beddoe, T.,Whisstock, J. C.,Wilce,M. C., Silins, S. L., Burrows,
J. M., Kjer-Nielsen, L., Kostenko, L., Purcell, A. W., McCluskey, J., and
Rossjohn, J. (2005) T cell receptor recognition of a “super-bulged” major
histocompatibility complex class I-bound peptide. Nat. Immunol. 6,
1114–1122
55. Ekeruche-Makinde, J.,Miles, J. J., vandenBerg,H.A., Skowera,A.,Cole,D.K.,
Dolton, G., Schauenburg, A. J. A., Tan, M. P., Pentier, J. M., Llewellyn-Lacey,
S., Miles, K. M., Bulek, A. M., Clement, M., Williams, T., Trimby, A., Bailey,
M.,Rizkallah, P., Rossjohn, J., Peakman,M., Price,D.A., Burrows, S.R., Sewell,
A. K., and Wooldridge, L. (2013) Peptide length determines the outcome of
TCR/peptide-MHCI engagement. Blood 121, 1112–1123
56. Martinez, C. R., and Iverson, B. L. (2012) Rethinking the term “pi-stack-
ing.” Chem. Sci. 3, 2191
57. Cole, D. K., Laugel, B., Clement, M., Price, D. A., Wooldridge, L., and
Sewell, A. K. (2012) The molecular determinants of CD8 co-receptor
function. Immunology 137, 139–148
58. Purbhoo, M. A., Boulter, J. M., Price, D. A., Vuidepot, A. L., Hourigan,
C. S., Dunbar, P. R., Olson, K., Dawson, S. J., Phillips, R. E., Jakobsen, B. K.,
Bell, J. I., and Sewell, A. K. (2001) The human CD8 coreceptor effects
cytotoxic T cell activation and antigen sensitivity primarily by mediating
complete phosphorylation of the T cell receptor  chain. J. Biol. Chem.
276, 32786–32792
59. Wooldridge, L., van den Berg, H. A., Glick, M., Gostick, E., Laugel, B.,
Hutchinson, S. L., Milicic, A., Brenchley, J. M., Douek, D. C., Price, D. A.,
and Sewell, A. K. (2005) Interaction between the CD8 coreceptor and
major histocompatibility complex class I stabilizes T cell receptor-antigen
complexes at the cell surface. J. Biol. Chem. 280, 27491–27501
60. Melenhorst, J. J., Scheinberg, P., Chattopadhyay, P. K., Lissina, A., Gostick,
E., Cole, D. K., Wooldridge, L., van den Berg, H. A., Bornstein, E., Hensel,
N. F., Douek, D. C., Roederer, M., Sewell, A. K., Barrett, A. J., and Price,
D. A. (2008) Detection of low avidity CD8 T cell populations with core-
ceptor-enhanced peptide-major histocompatibility complex class I te-
tramers. J. Immunol. Methods 338, 31–39
61. Cole, D. K., Yuan, F., Rizkallah, P. J., Miles, J. J., Gostick, E., Price, D. A.,
Gao, G. F., Jakobsen, B. K., and Sewell, A. K. (2009) Germ line-governed
recognition of a cancer epitope by an immunodominant human T-cell
receptor. J. Biol. Chem. 284, 27281–27289
62. Uchtenhagen, H., Abualrous, E. T., Stahl, E., Allerbring, E. B., Sluijter, M.,
Zacharias, M., Sandalova, T., van Hall, T., Springer, S., Nygren, P.-Å., and
Achour, A. (2013) Proline substitution independently enhances H-2D(b)
complex stabilization and TCR recognition of melanoma-associated pep-
tides. Eur. J. Immunol. 43, 3051–3060
63. Borbulevych, O. Y., Insaidoo, F. K., Baxter, T. K., Powell, D. J., Jr., Johnson,
L. A., Restifo, N. P., and Baker, B. M. (2007) Structures of MART-126/
27–35 peptide/HLA-A2 complexes reveal a remarkable disconnect be-
tween antigen structural homology and T cell recognition. J. Mol. Biol.
372, 1123–1136
64. Collins, E. J., Garboczi, D. N., andWiley, D. C. (1994) Three-dimensional
structure of a peptide extending from one end of a class I MHC binding
site. Nature 371, 626–629
65. Tenzer, S.,Wee, E., Burgevin, A., Stewart-Jones, G., Friis, L., Lamberth, K.,
Chang, C. H., Harndahl, M., Weimershaus, M., Gerstoft, J., Akkad, N.,
Klenerman, P., Fugger, L., Jones, E. Y., McMichael, A. J., Buus, S., Schild,
H., van Endert, P., and Iversen, A. K. N. (2009) Antigen processing influ-
ences HIV-specific cytotoxic T lymphocyte immunodominance.Nat. Im-
munol. 10, 636–646
66. Borbulevych, O. Y., Piepenbrink, K. H., Gloor, B. E., Scott, D. R., Sommese,
R. F., Cole, D. K., Sewell, A. K., and Baker, B. M. (2009) T cell receptor
cross-reactivity directed by antigen-dependent tuning of peptide-MHC
molecular flexibility. Immunity 31, 885–896
67. Tynan, F. E., Reid, H. H., Kjer-Nielsen, L., Miles, J. J., Wilce, M. C. J.,
Kostenko, L., Borg, N. A., Williamson, N. A., Beddoe, T., Purcell, A. W.,
Burrows, S. R., McCluskey, J., and Rossjohn, J. (2007) A T cell receptor
flattens a bulged antigenic peptide presented by a major histocompatibil-
ity complex class I molecule. Nat. Immunol. 8, 268–276
68. Lybarger, L., Yu, Y. Y. L., Miley, M. J., Fremont, D. H., Myers, N., Primeau,
T., Truscott, S. M., Connolly, J. M., and Hansen, T. H. (2003) Enhanced
immune presentation of a single-chain major histocompatibility complex
class Imolecule engineered to optimize linkage of aC-terminally extended
peptide. J. Biol. Chem. 278, 27105–27111
Flexible Peptide-MHC Binding of a T1D Epitope
JULY 31, 2015•VOLUME 290•NUMBER 31 JOURNAL OF BIOLOGICAL CHEMISTRY 18933
 at U
N
IV
 W
A
LES CO
LL O
F CA
RD
IF on A
ugust 18, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Wong and David K. Cole
Andrew Trimby, Andrew K. Sewell, F. Susan
Leenheer, Pierre J. Rizkallah, Konrad Beck, 
Chihiro Motozono, James A. Pearson, Evy De
  
Peptide
Accommodate an Insulin-derived 10-Mer
Complex Class I Binding Groove to 
Distortion of the Major Histocompatibility
Immunology:
doi: 10.1074/jbc.M114.622522 originally published online June 17, 2015
2015, 290:18924-18933.J. Biol. Chem. 
  
 10.1074/jbc.M114.622522Access the most updated version of this article at doi: 
  
.JBC Affinity SitesFind articles, minireviews, Reflections and Classics on similar topics on the 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
  
 http://www.jbc.org/content/290/31/18924.full.html#ref-list-1
This article cites 67 references, 27 of which can be accessed free at
 at U
N
IV
 W
A
LES CO
LL O
F CA
RD
IF on A
ugust 18, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
